18:56 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
06:02 , Aug 10, 2018 |  BC Extra  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
22:18 , Jun 23, 2017 |  BioCentury  |  Finance

Synthetic vitality

Versant Ventures and MPM Capital backed Repare Therapeutics Inc. with 2017’s largest series A round to get the synthetic lethality play to clinical proof of concept and possibly an exit. Repare emerged from stealth mode...
19:39 , Jun 23, 2017 |  BC Week In Review  |  Financial News

Repare launches with $68M series A

On June 22, cancer company Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures, which founded the company, co-led the round with MPM Capital. Also participating were Fonds de...
11:45 , Jun 22, 2017 |  BC Extra  |  Financial News

Repare launches with $68M

Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures, which founded the company, co-led the round with MPM Capital. Also participating were Fonds de solidarité FTQ, the Celgene Switzerland...
11:03 , Jun 22, 2017 |  BC Innovations  |  Emerging Company Profile

Repare in progress

With a $68 million series A co-led by Versant Ventures and MPM Capital, Repare Therapeutics Inc. emerged from 18 months of stealth today, making a splash in the growing pool of newcos targeting cancer via...
07:00 , Sep 26, 2016 |  BioCentury  |  Finance

Damage control

SV Life Sciences is going back for seconds in DNA damage repair, leading a $33.2 million series A round for Artios Pharma Ltd. This time, the firm is building the company for the long term...
07:00 , Sep 21, 2016 |  BC Extra  |  Financial News

Artios launches with $33.2M

Cancer newco Artios Pharma Ltd. (Cambridge, U.K.) raised $33.2 million in a series A round led by SV Life Sciences. Merck Ventures, Imperial Innovations Group plc (LSE:IVO), Arix Bioscience plc, the CRT Pioneer Fund of...
08:00 , Feb 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DNA-directed DNA polymerase θ (POLQ); poly(ADP-ribose) polymerase (PARP)

Cancer INDICATION: Cancer Cell culture and mouse studies suggest inhibiting POLQ could help treat cancers deficient in homologous recombination (HR) or homology-directed DNA repair. In a human breast cancer cell line with compromised homology-directed repair, shRNA knockdown...
08:00 , Feb 26, 2015 |  BC Innovations  |  Translation in Brief

The case for POLQ

DNA repair is a prime target for errors that can cause cancer, and the backup DNA repair system "alternative NHEJ" is particularly prone to mistakes that can give rise to tumors. Two groups have shown...